Compare BVS & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BVS | TBPH |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 783.2M | 908.9M |
| IPO Year | 2016 | 2013 |
| Metric | BVS | TBPH |
|---|---|---|
| Price | $11.85 | $16.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $14.00 | ★ $18.40 |
| AVG Volume (30 Days) | 706.8K | ★ 906.3K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 163.46 | ★ 279.13 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $568,087,000.00 | $15,386,000.00 |
| Revenue This Year | $7.52 | $8.46 |
| Revenue Next Year | $7.06 | N/A |
| P/E Ratio | $287.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.81 | $10.82 |
| 52 Week High | $12.53 | $21.03 |
| Indicator | BVS | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 58.18 | 50.57 |
| Support Level | $8.04 | $16.17 |
| Resistance Level | $12.53 | $17.21 |
| Average True Range (ATR) | 0.54 | 0.11 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 41.30 | 12.50 |
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.